Enliven Therapeutics director plans $560K share sale

The proposed sale is identified as being under a Rule 10b5-1 plan adopted October 19, 2025.

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. (ELVN) director Helen Collins filed notice to sell 15,000 common shares, with an aggregate market value of $559,800 and an approximate sale date of October 19, 2026. Jefferies LLC is listed as broker. The notice says all sales are to be made under a previously signed/adopted Rule 10b5-1 selling plan dated October 19, 2025. It also lists sales of 5,000 shares on August 17, 2026 and 5,000 shares on September 17, 2026.

Key Figures

Proposed sale: 15,000 common shares Aggregate market value: $559,800 Approximate sale date: October 19, 2026 +2 more

5 metrics

Proposed sale 15,000 common shares Helen Collins' notice

Aggregate market value $559,800 Proposed sale

Approximate sale date October 19, 2026 Proposed sale

Shares sold 5,000 shares August 17, 2026

Shares sold 5,000 shares September 17, 2026

Key Terms

Rule 144, 10b5-1 Selling plan, Stock Options

3 terms

Rule 144 regulatory

"paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 Selling plan regulatory

"10b5-1 Selling plan dated 10/19/2025"

Stock Options financial

"Stock Options"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ELVN shares is Helen Collins proposing to sell?

The notice lists a proposed sale of 15,000 common shares, with an aggregate market value of $559,800 and an approximate sale date of October 19, 2026.

Was Helen Collins's planned ELVN sale made under a 10b5-1 plan?

The notice says all sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated October 19, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/19/2026 - 04:17 PM EDT Accepted by SEC EDGAR 10/19/2026 - 04:16 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001701247
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Enliven Therapeutics, Inc.
SEC File Number	001-39247
Address of Issuer	205 PARK ROAD BURLINGAME CALIFORNIA 94010
Phone	7206478519
Name of Person for Whose Account the Securities are To Be Sold	Collins Helen Louise
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Avenue, 4th Floor New York NY 10022	15000	559800.00	73000000	10/19/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/09/2022	Stock Options	Enliven Therapeutics, Inc			15000	08/09/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Helen Collins 205 Park Rd. Burlingame CA 94010	Enliven Therapeutics	08/17/2026	5000	292930.00
Helen Collins 205 Park Rd. Burlingame CA 94010	Enliven Therapeutics	09/17/2026	5000	251753.75

144: Remarks and Signature

Remarks	All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 10/19/2025, and all representations regarding material non-public information were made as of the adoption of the plan.
Date of Notice	10/19/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	10/19/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Helen Collins
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)